Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

We report long-term clinical outcomes and immune responses observed from a phase 1 trial of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with metastatic melanoma. Twenty-four patients previously untreated with checkpoint blockade were enrolled. The agonistic CD40 mAb CP...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Bajor, David L., Mick, Rosemarie, Riese, Matthew J., Huang, Alex C., Sullivan, Brendan, Richman, Lee P., Torigian, Drew A., George, Sangeeth M., Stelekati, Erietta, Chen, Fang, Melenhorst, J. Joseph, Lacey, Simon F., Xu, Xiaowei, Wherry, E. John, Gangadhar, Tara C., Amaravadi, Ravi K., Schuchter, Lynn M., Vonderheide, Robert H.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6169575/
https://ncbi.nlm.nih.gov/pubmed/30288340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1468956
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars